Clinicopathological features and survival outcomes in bone-only metastatic breast cancer patients stratified by hormone receptor status: a tertiary care study

Irfan Rasool Gadda; Shivwani Kotwal; Dar Abdul Waheed; Devraj

doi:10.18203/2320-6012.ijrms20250979

Authors

Irfan Rasool Gadda Department of Radiation Oncology, Government Medical College, Srinagar, Jammu and Kashmir, India
Shivwani Kotwal Department of Physiology, Government Medical College, Jammu, Jammu and Kashmir, India
Dar Abdul Waheed Department of Radiation Oncology, Government Medical College, Srinagar, Jammu and Kashmir, India
Devraj Department of Social and Preventive Medicine, Government Medical College, Jammu, Jammu and Kashmir, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20250979

Keywords:

Bone mets, Breast carcinoma, Hormone receptor

Abstract

Background: Bone metastatic disease is common across all breast cancer subtypes. Patients with hormone receptor (HR)-positive breast cancer tend to have the greatest predilection for developing bone metastases and have better survival outcomes; unlike organotypic metastasis to visceral organs in triple-negative breast cancer. In this retrospective study, we compared the features and survival of these bone metastatic breast cancer subgroups and demonstrated that different ER and PR statuses contribute to varied survival outcomes.

Methods: It was a single‑institute retro prospective study. Out of the 200 HPR-proven cases of breast carcinoma, 100 patients were eligible for the study who presented/developed bone metastases. Patients with visceral mets were excluded from the study. Based on ER, PR and HER2 neu, status patients were divided into four groups.

Results: Out of 100 patients taken for this study 45 were ER+ PR+, 20 were Er-,PR-, 18 were ER-, PR +, and 17 were ER+,PR-.and the mean age in the study groups was 49.5±.5. Higher tumour grade and lymph node positivity was observed in ER- PR- and ER- PR+ as compared to hormone-positive groups. In our study group percentage of bone mets was higher in ER +, PR+(31.11 ) and ER+ PR- (52.63%),While as it was similar in Er-,PR- and ER-, PR + patients. The overall survival of ER+ PR- was 94.1% followed by ER +, PR+(86.7%) while patients with ER-, PR- had 30.0% and ER-, PR + 27.8%.

Conclusions: Different ER and PR statuses in breast cancer exert a significant impact on bone metastasis incidence and survival condition of bone metastatic breast cancer. Hormone receptor‑positive tumours show a predilection for bones as the first site of relapse and better overall survival as compared to hormone‑receptor‑negative tumours.

Metrics

Metrics Loading ...

References

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN. Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49. DOI: https://doi.org/10.3322/caac.21660

International Agency for Research on Cancer. India Source: Globocan; 2020. Available at: https://acsjournals.onlinelibrary.wiley.com/doi/abs/10.3322/caac.21660. Accessed on 01 February 2025.

Li CI, Uribe DJ, Daling JR. Clinical characteristics of different histologic types of breast cancer. Br J Cancer. 2005;93(9):1046-1052. DOI: https://doi.org/10.1038/sj.bjc.6602787

Li CI, Anderson BO, Daling JR, Moe RE. Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA. 2003;289(11):1421-4. DOI: https://doi.org/10.1001/jama.289.11.1421

Aurilio G, Disalvatore D, Pruneri G, Bagnardi V, Viale G, Curigliano G, et al. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. Eur J Cancer. 2014;50(2):277-89. DOI: https://doi.org/10.1016/j.ejca.2013.10.004

Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003;3(6):537-49. DOI: https://doi.org/10.1016/S1535-6108(03)00132-6

Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nature Revi Cancer. 2002;2(8):584-93. DOI: https://doi.org/10.1038/nrc867

D'Oronzo S, Coleman R, Brown J, Silvestris F. Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management. J B Oncol. 2019;15:100205. DOI: https://doi.org/10.1016/j.jbo.2018.10.004

Hofbauer L, Rachner T, Coleman R, Jakob F. Endocrine aspects of bone metastases. Lancet Diabetes Endocrinol. 2014;2(6):500-12. DOI: https://doi.org/10.1016/S2213-8587(13)70203-1

Parkes A, Clifton K, Al-Awadhi A, Oke O, Warneke CL, Litton JK, et al. Characterization of bone only metastasis patients with respect to tumor subtypes. NPJ Breast Cancer. 2018;4(1):2. DOI: https://doi.org/10.1038/s41523-018-0054-x

Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397(10286):1750-69. DOI: https://doi.org/10.1016/S0140-6736(20)32381-3

Liang Y, Zhang H, Song X, Yang Q. Metastatic heterogeneity of cancer: Molecular mechanism and potential therapeutic targets. Semin Cancer Biol. 2020;60:14-27. DOI: https://doi.org/10.1016/j.semcancer.2019.08.012

Chen MT, Sun HF, Zhao Y, Fu WY, Yang LP, Gao SP, et al. Comparison of patterns and prognosis among distant metastatic breast cancer patients by age groups: A SEER population‑based analysis. Sci Rep. 2017;7:9254. DOI: https://doi.org/10.1038/s41598-017-10166-8

Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987;55(1):61‑6. DOI: https://doi.org/10.1038/bjc.1987.13

Savci‑Heijink CD, Halfwerk H, Hooijer GK, Horlings HM,Wesseling J, van de Vijver MJ. Retrospective analysis of metastatic behaviour of breast cancer subtypes. Breast Cancer Res Treat. 2015;150:547‑57. DOI: https://doi.org/10.1007/s10549-015-3352-0

Jiang X, Chen G, Sun L, Liu C, Zhang Y, Liu M, Liu C. Characteristics and survival in bone metastatic breast cancer patients with different hormone receptor status: A population-based cohort study. Frontiers in Oncology. 2022;12:977226. DOI: https://doi.org/10.3389/fonc.2022.977226

Ananya Pareek, O. P. Singh, Veenita Yogi, H. U. Ghori, Vivek Tiwari, Pallavi Redhu Bone metastases incidence and its correlation with hormonal and human epidermal growth factor receptor 2 neuroreceptors in breast cancer J Can Res Ther. 2019;15(5):971-5. DOI: https://doi.org/10.4103/jcrt.JCRT_235_18

Cazzaniga ME, Dogliotti L, Cascinu S, Barni S, Labianca R, Chiara S, et al. Diagnosis, management and clinical outcome of bone metastases in breast cancer patients: Results from a prospective, multicenter study. Oncol. 2006;71(5-6):374-81. DOI: https://doi.org/10.1159/000107772